Drug Information
Drug (ID: DG00328) and It's Reported Resistant Information
Name |
Ceftolozane sulfate
|
||||
---|---|---|---|---|---|
Synonyms |
Ceftolozane; CXA-101; CXA-301; CXA-301); Cephalosporin derivatives, Astellas; Cephalosporinderivatives, Calixa Therapeutics; FR-193879; FR-264205; FR-295389; CXA-101 (inhaled), Calixa; CXA-101 (inhaled), Cubist; Cephalosporin derivative (H pylori/P aeruginosa infection), Astellas; CXA-101 (inhaled, bacterial lung infection), Cubist
Click to Show/Hide
|
||||
Indication |
In total 1 Indication(s)
|
||||
Structure | |||||
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(2 diseases)
Bacterial infection [ICD-11: 1A00-1C4Z]
[2]
Malaria [ICD-11: 1F45]
[1]
|
||||
Target | Bacterial Penicillin binding protein (Bact PBP) | NOUNIPROTAC | [1] | ||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
Formula |
C23H32N12O12S3
|
||||
IsoSMILES |
CC(C)(C(=O)O)O/N=C(\\C1=NSC(=N1)N)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)O.OS(=O)(=O)[O-]
|
||||
InChI |
1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/b31-11+;/t12-,18-;/m1./s1
|
||||
InChIKey |
UJDQGRLTPBVSFN-GZGOMJRCSA-N
|
||||
PubChem CID | |||||
TTD Drug ID | |||||
DrugBank ID |
Type(s) of Resistant Mechanism of This Drug
DISM: Drug Inactivation by Structure Modification
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-01: Infectious/parasitic diseases
Bacterial infection [ICD-11: 1A00-1C4Z]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Beta-lactamase (BLA) | [2] | |||
Molecule Alteration | Missense mutation | p.Y221H |
||
Resistant Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli TOP10 | 83333 | ||
Escherichia coli EC13 | 562 | |||
Experiment for Molecule Alteration |
Whole genome sequencing assay | |||
Experiment for Drug Resistance |
Disk diffusion test assay | |||
Mechanism Description | The CMY-136 Beta-lactamase, a Y221H point mutant derivative of CMY-2,confers an increased level of resistance to ticarcillin, cefuroxime, cefotaxime, and ceftolozane/tazobactam. |
Malaria [ICD-11: 1F45]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: CAM-1 carbapenemase (CAM1) | [1] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Pseudomonas infection [ICD-11: 1F45.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli TOP10 | 83333 | ||
Pseudomonas aeruginosa N17-01167 | 287 | |||
Pseudomonas aeruginosa N17-01173 | 287 | |||
Pseudomonas aeruginosa N17-02436 | 287 | |||
Pseudomonas aeruginosa N17-02437 | 287 | |||
Experiment for Molecule Alteration |
Whole genome sequencing assay | |||
Experiment for Drug Resistance |
Vitek 2 assay; Etest assay | |||
Mechanism Description | A novel class B Beta-lactamase gene, blaCAM-1, exhibited resistance to imipenem, meropenem, doripenem, cefotaxime, ceftazidime, cefoxitin, piperacillin/tazobactam, ceftazidime/avibactam and ceftolozane/tazobactam. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.